Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.
L. Gore
No relevant relationships to disclose
K. Lewis
No relevant relationships to disclose
D. D. Von Hoff
Research Funding - Ardea Biosciences
G. J. Weiss
No relevant relationships to disclose
R. K. Ramanathan
No relevant relationships to disclose
A. A. Adjei
Research Funding - Ardea Biosciences
G. K. Dy
No relevant relationships to disclose
W. W. Ma
No relevant relationships to disclose
N. J. Clendeninn
Consultant or Advisory Role - Ardea Biosciences
Stock Ownership - Ardea Biosciences
D. P. Leffingwell
Consultant or Advisory Role - Ardea Biosciences
B. Sheedy
Stock Ownership - Ardea Biosciences
C. Iverson
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
J. N. Miner
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
Z. Shen
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
L. Yeh
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
R. L. Dubowy
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
M. Jeffers
Employment or Leadership Position - Bayer
P. Rajagopalan
Employment or Leadership Position - Bayer
C. D. Weekes
Honoraria - Ardea Biosciences
Research Funding - Ardea Biosciences